
CHNXF
Healthcare · Biotechnology · $627,627 market cap
$0.00760.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Oct 31, 2023
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jan 1, 2025 | Before the open | — | -0.01 | — |
| Sep 27, 2024 | After the close | — | -0.00 | — |
| Jul 2, 2024 | Before the open | — | -0.00 | — |
| Jan 3, 2024 | Before the open | — | -0.01 | — |
| Sep 29, 2023 | Before the open | -0.03 | -0.01 | +66.7% |
| Jun 29, 2023 | After the close | -0.03 | 0.00 | +104.7% |
| Mar 29, 2023 | Time not confirmed | -0.03 | -0.04 | -33.3% |
| Dec 28, 2022 | After the close | -0.03 | -0.04 | -33.3% |
| Sep 28, 2022 | After the close | -0.03 | -0.03 | 0.0% |
| May 19, 2022 | After the close | -0.03 | -0.02 | +33.3% |
| Mar 30, 2022 | Time not confirmed | — | -0.02 | — |
| Dec 21, 2021 | After the close | -0.03 | -0.06 | -100.0% |
| Sep 30, 2021 | After the close | -0.03 | -0.03 | 0.0% |
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of orthopaedic and sports medicine surgeries in Canada. It develops Ortho-R, a biopolymer for rotator cuff repair; and Ortho-M, a biopolymer for meniscus repair. The company was formerly known as Ortho Regenerative Technologies…
| May 31, 2021 | After the close | -0.02 | -0.04 | -100.0% |
| Mar 31, 2021 | Time not confirmed | — | -0.03 | — |
| Dec 17, 2020 | After the close | -0.03 | -0.03 | 0.0% |